JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.420
-0.050 (-2.02%)
Apr 17, 2026, 4:08 PM HKT
Market Cap981.65M +14.8%
Revenue (ttm)315.65M +79.3%
Net Income-617.93M
EPS-1.49
Shares Out405.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume862,000
Average Volume1,142,452
Open2.430
Previous Close2.470
Day's Range2.350 - 2.480
52-Week Range1.400 - 6.440
Beta1.85
RSI63.02
Earnings DateMar 26, 2026

About HKG:2126

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 314
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2126
Full Company Profile

Financial Performance

In 2025, HKG:2126's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements